Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III sold 92,779 shares of the stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $40.05, for a total transaction of $3,715,798.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ:XNCR opened at $37.01 on Friday. Xencor Inc has a 12 month low of $18.97 and a 12 month high of $43.39. The stock has a market capitalization of $2.09 billion, a PE ratio of -35.25 and a beta of 1.63.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.16). Xencor had a negative return on equity of 18.07% and a negative net margin of 137.35%. research analysts predict that Xencor Inc will post -2.33 earnings per share for the current year.
Several equities research analysts have weighed in on XNCR shares. Wedbush increased their price target on shares of Xencor from $38.00 to $39.00 and gave the company an “outperform” rating in a research report on Monday, March 19th. BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 9th. BTIG Research assumed coverage on shares of Xencor in a research report on Thursday, June 7th. They issued a “buy” rating and a $56.00 target price for the company. Zacks Investment Research raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 17th. Finally, ValuEngine raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 22nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $37.88.
Several institutional investors have recently modified their holdings of the stock. Barclays PLC increased its stake in shares of Xencor by 39.1% in the 1st quarter. Barclays PLC now owns 8,960 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 2,518 shares in the last quarter. Vident Investment Advisory LLC increased its stake in shares of Xencor by 5.9% in the 4th quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock worth $1,303,000 after acquiring an additional 3,289 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Xencor in the 1st quarter worth about $115,000. Victory Capital Management Inc. increased its stake in shares of Xencor by 12.3% in the 1st quarter. Victory Capital Management Inc. now owns 38,114 shares of the biopharmaceutical company’s stock worth $1,142,000 after acquiring an additional 4,160 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Xencor by 0.9% in the 1st quarter. Northern Trust Corp now owns 481,027 shares of the biopharmaceutical company’s stock worth $14,421,000 after acquiring an additional 4,206 shares in the last quarter. Institutional investors own 79.54% of the company’s stock.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.